Eletriptan vs sumatriptan

Sandrini, Giorgio; Färkkilä, Markus; Burgess, Gary; Forster, Estrella M.; Haughie, Scott

doi:10.1212/wnl.59.8.1210

Cited by 87 publications

(115 citation statements)

References 18 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Eletriptan has demonstrated within-patient consistency of response based on three previous studies using a randomized, double-blind, placebo-controlled, parallelgroup design (10)(11)(12). For eletriptan 40 mg (ELE-40), consistency of response on two out of three attacks ranged from 63% to 77%, and for eletriptan 80 mg (ELE-80), two out of three consistency ranged from 72% to 82%.…”

Section: Introductionmentioning

confidence: 99%

Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study

Almas

Tepper

Landy³

et al. 2013

Cephalalgia

View full text Add to dashboard Cite

Objective: The current study evaluated the consistency of eletriptan response. Methods: Using a within-patient crossover design, patients with migraine completed a three-attack, open-label, lead-in period, before being treated, double-blind for four attacks, with either eletriptan 40 mg (ELE-40; N ¼ 539) or eletriptan 80 mg (ELE-80; N ¼ 432); placebo was randomly substituted for the treatment of one attack. Results: On an a priori analysis of within-patient consistency, double-blind treatment was associated with similar 2 hour headache response rates using a !2/3 response criterion for ELE-40 (77%) and ELE-80 (73%), and using a 3/3 response criterion for ELE-40 (46%) and ELE-80 (47%). Within-patient consistency in achieving pain-free status at 2 hours using a !2/3 criterion was slightly higher on ELE-40 (42%) compared with ELE-80 (38%), and was similar using the 3/3 criterion (18% on ELE-40, 17% on ELE-80). On a repeated measures logistic regression analysis across all treated attacks, the probability of achieving a headache response at 2 hours ranged from 71% to 74% on ELE-40 vs. 17% to 28% on placebo (p < 0.0001), and from 66% to 74% on ELE-80 vs. 21% to 27% on placebo (p < 0.0001). The incidence, per attack, of adverse events was low for both ELE-40 and ELE-80. Few adverse events occurred with incidence !10% on ELE-40 (asthenia, 5.0%) or ELE-80 (asthenia, 10%; nausea, 5.8%). Discontinuations because of adverse events were 0.2% on ELE-40, and 1.6% on ELE-80 Conclusion: In this multiple attack study, eletriptan was well-tolerated and demonstrated consistent and significant efficacy in the treatment of migraine.Clinicaltrials.Gov Identifier: NCT01859481

show abstract

Section: Introductionmentioning

confidence: 99%

Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study

Almas

Tepper

Landy³

et al. 2013

Cephalalgia

View full text Add to dashboard Cite

show abstract

“…In two out of three comparative trials, eletriptan 40 mg demonstrated a significantly greater efficacy for headache and pain-free response at 2 h compared with sumatriptan 100 mg [32,33]. When headache response at 1 h was considered, eletriptan 40 mg showed a significantly higher rate compared with sumatriptan 100 mg [31,33].…”

Section: Eletriptan Versus Sumatriptanmentioning

confidence: 97%

Eletriptan: a review and new perspectives

Sandrini

Perrotta

Nappi

2006

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Eletriptan is a second-generation 5-hydroxytryptamine(1B/1D) receptor agonist, or triptan, indicated for the acute treatment of migraine. Eletriptan has a favorable pharmacokinetic and pharmacodynamic profile expressed by bioavailability, half-life and high selectivity for cranial arteries. It has been shown to be effective and well tolerated in a wide preapproval development program, which included over 11,000 patients and treated more than 74,000 migraine attacks. In clinical trials, eletriptan has been demonstrated to be one of the most effective oral therapies for the acute treatment of migraine and has shown a very high safety and tolerability profile across the studies performed. Eletriptan showed the most favorable cost-effectiveness profile when compared with other agents in its class.

show abstract

“…The results of these trials consistently showed eletriptan's (40 and 80 mg) clinical efficacy and onset of action to be superior when compared with oral sumatriptan 100 mg. Both sumatriptan and eletriptan were well tolerated, with low incidence of adverse effects [Goadsby et al 2000;Mathew et al 2003b;Sandrini et al 2002]. Moreover, eletriptan (compared with placebo) has been demonstrated as effective in treating acute migraine in previous nonresponders, or patients not tolerant to sumatriptan [Färkkilä et al 2003].…”

Section: Eletriptan: Efficacy In Head-to-head Studiesmentioning

confidence: 99%

Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response

Capi

Curto

Lionetto

et al. 2016

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT 1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks. In this paper, we review the recent data on eletriptan clinical efficacy, safety, and tolerability, and potential clinically relevant interactions with other drugs. Among triptans, eletriptan shows a consistent and significant clinical efficacy and a good tolerability profile in the treatment of migraine, especially for patients with cardiovascular risk factors without coronary artery disease. It shows the most favorable clinical response, together with sumatriptan injections, zolmitriptan and rizatriptan. Additionally, eletriptan shows the most complex pharmacokinetic/dynamic profile compared with the other triptans. It is metabolized primarily by the CYP3A4 hepatic enzyme and therefore the concomitant administration of CYP3A4-potent inhibitors should be carefully evaluated. A relatively low risk of serotonin syndrome is given by the coadministration with serotoninergic drugs. No clinically relevant interaction has been found with drugs used for migraine prophylactic treatment or other acute drugs, with the exception of ergot derivatives that should not be co-administered with eletriptan.

show abstract

Eletriptan vs sumatriptan

Abstract: Oral eletriptan (40 mg and 80 mg) is effective, safe, and tolerable in the acute treatment of migraine and yields a consistent response.

Cited by 87 publications

References 18 publications

Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study

Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study

Eletriptan: a review and new perspectives

Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response

Contact Info

Product

Resources

About